AG
ALNY icon

AmeriFlex Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

AmeriFlex Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51K Buy
15
+6
+67% +$1.81K ﹤0.01% 1053
2026
Q1 		$2.98K Hold
9
– – ﹤0.01% 911
2025
Q4 		$3.58K Sell
9
-61
-87% -$27K ﹤0.01% 907
2025
Q3 		$31.9K Buy
+70
New +$28.5K 0.01% 548

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AmeriFlex Group's ALNY Position: Q2 2026 in Review

AmeriFlex Group increased its Alnylam Pharmaceuticals (ALNY) stake by 67% in Q2 2026, buying an estimated $1.81K and bringing the position to 15 shares worth $4.51K. The position accounts for ﹤0.01% of the portfolio, ranked #1053.

AmeriFlex Group first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $31.9K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • AmeriFlex Group held 15 shares of Alnylam Pharmaceuticals worth $4.51K as of Q2 2026.
  • AmeriFlex Group bought 6 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.81K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of AmeriFlex Group's portfolio in Q2 2026, its #1053 holding.
  • AmeriFlex Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • AmeriFlex Group's Alnylam Pharmaceuticals position peaked at $31.9K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on AmeriFlex Group's 13F filing for Q2 2026, filed 14 Aug 2026.